Miniatura

Fitxers

1-s2.0-S0735109722065299-main.pdf (587.45 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-11-01

Llicència de publicació

cc by (c) Butt, Jawad H. et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/191623

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jacc.2022.08.718

Resum

BACKGROUND Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy. OBJECTIVES This study examined the effects of dapagliflozin according to the presence or not of AF in the DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial. METHODS A total of 6,263 patients with HF with New York Heart Association functional class II-IV, left ventricular ejection fraction >40%, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomized to dapagliflozin or placebo. Clinical outcomes and the effect of dapagliflozin, according to AF status, were examined. The primary outcome was a composite of cardiovascular death or worsening HF. RESULTS Of the 6,261 patients with data on baseline AF, 43.3% had no AF, 18.0% had paroxysmal AF, and 38.7% had persistent/permanent AF. The risk of the primary endpoint was higher in patientswith AF, especially paroxysmal AF, driven by a higher rate ofHF hospitalization: no AF, HF hospitalization rate per 100 person-years (4.5 [95% CI: 4.0-5.1]), paroxysmal AF (7.5 [95% CI: 6.4-8.7]), and persistent/permanent AF (6.4 [95% CI: 5.7-7.1]) (P < 0.001). The benefit of dapagliflozin on the primary outcome was consistent across AF types: no AF, HR: 0.89 (95% CI: 0.74-1.08); paroxysmal AF, HR: 0.75 (95% CI: 0.58-0.97); persistent/permanent AF, HR: 0.79 (95% CI: 0.66-0.95) (Pinteraction = 0.49). Consistent effects were observed for HF hospitalization, cardiovascular death, all-cause mortality, and improvement in the KCCQ-TSS. CONCLUSIONS In DELIVER, the beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, irrespective of type of AF at baseline.

Matèries

Assaigs clínics, Insuficiència cardíaca

Matèries (anglès)

Clinical trials, Heart failure

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BUTT, Jawad h., KONDO, Toru, JHUND, Pardeep s., COMÍN COLET, Josep, DE BOER, Rudolf a., DESAI, Akshai s., HERNANDEZ, Adrian f., INZUCCHI, Silvio e., JANSSENS, Stefan p., KOSIBOROD, Mikhail n., LAM, Carolyn s. p., LANGKILDE, Anna maria, LINDHOLM, Daniel, MARTINEZ, Felipe, PETERSSON, Magnus, SHAH, Sanjiv j., THIERER, Jorge, VADUGANATHAN, Muthiah, VERMA, Subodh, WILDERÄNG, Ulrica, CLAGGETT, Brian l., SOLOMON, Scott d., MCMURRAY, John. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. _Journal of the American College of Cardiology_. 2022. Vol. 80, núm. 18, pàgs. 1705-1717. [consulta: 25 de febrer de 2026]. ISSN: 1558-3597. [Disponible a: https://hdl.handle.net/2445/191623]

Exportar metadades

JSON - METS

Compartir registre